Regeneron Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
REGN Regeneron Pharmaceuticals Inc
CDE Coeur Mining Inc
BRID Bridgford Foods Corp
SOR Source Capital Inc
RCLFW Rosecliff Acquisition Equity I Warrants Exp 11 Feb 2026 *W EXP 02/11/2026
FAST Fastenal Co
UKOMW Ucommune International Equity Warrant Exp 17th Nov 2025 *W EXP 11/17/2025
KMI Kinder Morgan Inc
RSG Republic Services Inc
TGEN Tecogen Inc
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Price
Delayed
$594.66
Day's Change
-1.90 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
601.88
Day's Low
588.92
Volume
(Light)

Today's volume of 298,489 shares is on pace to be much lighter than REGN's 10-day average volume of 606,305 shares.

298,489

REGN's position in the Biotechnology industry

Industry PeersREGNAMGNGILDINCYUTHR

Summary

Company ProfileRegeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human...
Go to GILD summary
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development...
Go to INCY summary
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso...
Go to UTHR summary
52-Week Change

VS. INDUSTRY
2.21%
-0.79%
-10.04%
-5.18%
28.66%
Market Cap

VS. INDUSTRY
$65.5B
$131.8B
$78.2B
$17.6B
$10.7B
Beta

VS. INDUSTRY
0.3
0.6
0.4
0.7
0.6
Dividend Yield

VS. INDUSTRY
--
3.15%
4.68%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
8.45x
24.29x
17.42x
18.86x
16.42x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$16.5B
$26.3B
$27.5B
$3.1B
$1.8B
Profit Margin

VS. INDUSTRY
48.06%
21.75%
16.35%
29.96%
38.87%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
56.36%
0.08%
-13.08%
51.40%
-7.98%
Revenue Growth (TTM)

VS. INDUSTRY
79.48%
4.58%
7.46%
15.24%
17.41%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.